Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro
- PMID: 9213241
- DOI: 10.1007/BF02934484
Trophic effects of glicentin on rat small-intestinal mucosa in vivo and in vitro
Abstract
To define the role of glicentin the active site of enteroglucagon, we evaluated the trophic effects of recombinant rat glicentin on rat small intestine and IEC-6 cells. In vivo, a significant increase was observed in jejunal wet weight, protein content, DNA content, and alkaline phosphatase activity after the subcutaneous administration of 100 micrograms/kg per day of glicentin for 2 weeks. In the ileum, however, there were no significant differences between the control versus glicentin groups in any of these parameters. Ornithine decarboxylase (ODC) activity 3.5 h after an intraperitoneal injection of glicentin was increased in the jejunal mucosa, but not in the ileal mucosa. In vitro, glicentin, at a dose of more than 100 ng/ml, significantly increased both tritium-thymidine incorporation and the number of IEC-6 cells. These findings indicate that glicentin exerts direct trophic effects on the rat small-intestinal mucosa and on the rat small-intestinal cell line, IEC-6, and that this peptide appears to be an active site of enteroglucagon.
Similar articles
-
Effect of glicentin on gut mucosal growth in rats with jejunal and ileal Thiry-Vella fistulas.J Pediatr Surg. 2003 Apr;38(4):579-84. doi: 10.1053/jpsu.2003.50126. J Pediatr Surg. 2003. PMID: 12677570
-
Effect of rat glicentin on intestinal adaptation in small intestine-resected rats.Ann N Y Acad Sci. 1998 Dec 11;865:601-5. doi: 10.1111/j.1749-6632.1998.tb11244.x. Ann N Y Acad Sci. 1998. PMID: 9928077 No abstract available.
-
Glicentin, an active enteroglucagon, has a significant trophic role on the small intestine but not on the colon in the rat.Aliment Pharmacol Ther. 2001 Oct;15(10):1681-6. doi: 10.1046/j.1365-2036.2001.01082.x. Aliment Pharmacol Ther. 2001. PMID: 11564010
-
Enteroglucagon.Annu Rev Physiol. 1997;59:257-71. doi: 10.1146/annurev.physiol.59.1.257. Annu Rev Physiol. 1997. PMID: 9074764 Review.
-
Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator.Curr Protein Pept Sci. 2004 Feb;5(1):51-65. doi: 10.2174/1389203043486946. Curr Protein Pept Sci. 2004. PMID: 14965320 Review.
Cited by
-
Postprandial Dynamics of Proglucagon Cleavage Products and Their Relation to Metabolic Health.Front Endocrinol (Lausanne). 2022 Jun 29;13:892677. doi: 10.3389/fendo.2022.892677. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35872982 Free PMC article. Clinical Trial.
-
Neurohormonal Changes in the Gut-Brain Axis and Underlying Neuroendocrine Mechanisms following Bariatric Surgery.Int J Mol Sci. 2022 Mar 19;23(6):3339. doi: 10.3390/ijms23063339. Int J Mol Sci. 2022. PMID: 35328759 Free PMC article. Review.
-
Proglucagon-Derived Peptides as Therapeutics.Front Endocrinol (Lausanne). 2021 May 18;12:689678. doi: 10.3389/fendo.2021.689678. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34093449 Free PMC article. Review.
-
The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome.ACS Pharmacol Transl Sci. 2019 Mar 1;2(2):134-142. doi: 10.1021/acsptsci.9b00016. eCollection 2019 Apr 12. ACS Pharmacol Transl Sci. 2019. PMID: 32219218 Free PMC article.
-
The Long Road to the Development of Effective Therapies for the Short Gut Syndrome: A Personal Perspective.Dig Dis Sci. 2019 Oct;64(10):2717-2735. doi: 10.1007/s10620-019-05779-0. Dig Dis Sci. 2019. PMID: 31410752 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials